4203 articles
Apellis Pharmaceuticals announced Australia’s Therapeutic Goods Administration (TGA) has approved Syfovre (pegcetacoplan intravitreal injection) for the every-other-month treatment of adults with geog
Ashvattha Therapeutics has secured additional financing up to US$50 million (NZ$88.4m) for its at-home monthly subcutaneously-administered treatment for neovascular age-related macular degeneration (n
Building on last year’s success, Silmo 2025 preparations are well underway, with organisers promising a unique edition with exclusive content and interactive experiences immersing visitors in the world of optical innovation.
Responding to the growing global issue of high myopia, Hoya Vision Care Australia and New Zealand is expanding its Miyosmart power range, unlocking spectacle lenses for patients with a broader range o
Hirdesh Nair has moved into the role of regional sales manager at Johnson & Johnson Vision Care (J&J VC). Based out of Melbourne, he will be covering Victoria, Tasmania, South Australia, New Zealand and Western Australia.
Danish brand Inface has been re-invented to target the young and young at heart, with its latest collections putting colour front and centre. Models such as Toffee (shown here in aqua dark matt) feature strong contrasting colour temples to make a statement.
Dame Lydia Ko, New Zealand’s 2024 Olympic gold medallist in women's golf and the youngest inductee of the LPGA Hall of Fame, has entered a two-year partnership with sunglasses brand Maui Jim.
Shining a spotlight on glaucoma this month, Glaucoma New Zealand (GNZ) is sharing patient stories explaining their experiences of the disease and is inviting the country’s optometrists and ophthalmologists to help them share the message and keep referring patients.
Alcon has acquired Melbourne-based Cylite, known for its hyperparallel optical coherence tomography (HP-OCT) technology. “We are excited about the potential of this technology in whole-eye OCT imagi
US researchers have found a possible link between weight-loss drugs and ophthalmic complications
Led by EssilorLuxottica, a five-year research and innovation project aims to set a new standard in the med-technology space with personalised myopia treatment through medical optics.
Glaukos has announced positive clinical updates for its iDose sustained release procedural pharmaceutical platform. The tech company’s 36-month follow-up analysis of its two phase 3 iDoseTR (travopr
